Hillstar Bio has successfully closed a $67 million Series A financing round led by various investors. The funds will be used to advance their lead TRBV9 program and broaden their pipeline in precision immunotherapy.
Amount Raised
$67 Million
Round Type
Series A
BostonBiotechnologyHealth CareTherapeuticsInvestors
Description
Hillstar Bio, a biotechnology company, announced the successful closing of a $67 million Series A financing round. The funding was led by a syndicate of investors from the U.S., Europe, and Asia, including Droia Ventures, Frazier Life Sciences, Novo Holdings A/S, LifeArc Ventures, and Hummingbird Bioscience. The proceeds will fund the advancement of the company's lead TRBV9 program and progress their broader pipeline in autoimmune treatments. Hillstar Bio focuses on a precision-driven approach to target pathogenic immune cells while preserving healthy ones.
Quick answer
Hillstar Bio raised $67 Million in a Series A round, dated March 25, 2025. Investors: Droia Ventures, Frazier Life Sciences, Novo Holdings A/S, LifeArc Ventures and Hummingbird Bioscience. Hillstar Bio is based in Boston, Massachusetts, United States.
- How much did Hillstar Bio raise?
- Hillstar Bio raised $67 Million in a Series A round on March 25, 2025.
- Who invested in Hillstar Bio?
- Droia Ventures, Frazier Life Sciences, Novo Holdings A/S, LifeArc Ventures and Hummingbird Bioscience are named as investors in this round.
- What does Hillstar Bio do?
- Hillstar Bio is a biotechnology company focused on developing next-generation precision immunology therapies for autoimmune diseases.
- Where is Hillstar Bio based and how big is it?
- Hillstar Bio is based in Boston, Massachusetts, United States. Fundz records about 17 employees.
- Who are the decision-makers at Hillstar Bio?
- Fundz holds 1 contact at Hillstar Bio. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Hillstar Bio that raised within 45 days of this round, from Fundz verified event records.
- Cellestial Health raised an undisclosed amount (Pre-Seed) on May 9, 2025.
- ImmuneWalk Therapeutics raised $7M (Seed) on May 8, 2025.
- PAQ Therapeutics raised $39M (Series B) on May 7, 2025.
- Avammune Therapeutics raised $12M (Series A) on May 7, 2025.
- Paradigm Therapeutics raised $13M (Funding Round) on May 6, 2025.
- Azora Therapeutics, Inc. (DE) raised $4.8M on May 2, 2025.
Who to call at Hillstar Bio, and when
A new round usually means Hillstar Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Hillstar Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Hillstar Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Hillstar Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Hillstar Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansHillstar Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.